Last month, the country's second-largest drug maker Dr Reddy's Laboratories had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.
A response was finally submitted to the US health regulator by Dr Reddy's on the context of that warning letter it had received last month.
Dr Reddy's Laboratories said that they would like to inform that the company has submitted a response to the US Food and Drug Administration (USFDA) in response to the letter.
DRL CEO G V Prasad had said the company is in the process of shifting some of the products from these plants to other facilities and considering third party assessment for its plants.
The US agency had asked the drug maker to provide a comprehensive evaluation of the extent of inaccuracies in recorded and reported data and include a detailed action plan to fully investigate the scale and root causes of "deficient documentation and data management practices".
View Latest News:
- Alexion’s FDA Approval for Drug Kanuma Listed as the 41st of Approvals in 2015
- Google Inc. Files Patent on Needle-Free Blood Drawing Device
- Researchers Find New Technique of Destroying Tumors Using Combined Ultrasound and Nanoparticle Chemotherapy
- Scientists Discover New Protein That Serves As Multi-tool Pocketknife While Processing Ribosomal RNA